Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 129.73B P/E 18.00 EPS this Y -9.10% Ern Qtrly Grth -12.90%
Income 8.02B Forward P/E 8.64 EPS next Y 4.00% 50D Avg Chg -4.00%
Sales 45.01B PEG -2.79 EPS past 5Y 13.30% 200D Avg Chg -12.00%
Dividend 4.00% Price/Book 4.03 EPS next 5Y -2.80% 52W High Chg -24.00%
Recommedations 2.70 Quick Ratio 1.24 Shares Outstanding 2.02B 52W Low Chg 3.00%
Insider Own 0.10% ROA 5.63% Shares Float 2.02B Beta 0.37
Inst Own 79.18% ROE 26.53% Shares Shorted/Prior 37.25M/31.49M Price 61.75
Gross Margin 76.63% Profit Margin 17.83% Avg. Volume 8,754,443 Target Price 56.00
Oper. Margin 17.01% Earnings Date Apr 25 Volume 9,548,659 Change 0.36%
About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company News
03/28/24 UPDATE 2-Bristol Myers' bowel disease drug fails in late-stage study
03/28/24 Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…
03/28/24 Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
03/28/24 Is Bristol Myers Squibb Stock a Buy?
03/28/24 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
03/27/24 Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts
03/26/24 20 Countries with the Highest Heart Disease Deaths Per Capita
03/26/24 Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
03/25/24 Bristol-Myers Squibb Company (BMY) Impacted by Delay in New Product Launches
03/25/24 Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
03/22/24 Bristol-Myers Squibb (NYSE:BMY) Has Announced A Dividend Of $0.60
03/21/24 Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
03/21/24 New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding
03/21/24 Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion
03/20/24 Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
03/20/24 UPDATE 2-Bristol Myers' Opdivo-Yervoy combo meets main goal in liver cancer trial
03/20/24 Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
03/19/24 Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in "SO, Have You Found It?" Campaign
03/18/24 James D. Robinson III, Who Tried to Diversify American Express Far Beyond Cards, Dies at 88
03/18/24 Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion
BMY Chatroom

User Image DonCorleone77 Posted - 1 hour ago

$MTEM $BMY Bristol Myers ends collaboration agreement with Molecular Templates Molecular Templates (MTEM) said that on March 13, Bristol-Myers Squibb (BMY) notified the company that following a corporate portfolio prioritization process, it does not intend to continue the research collaboration it entered into with the Molecular pursuant to the BMS collaboration agreement and would be terminating the agreement in its entirety. The termination will be effective on June 13, or 90 days following the company's receipt of Bristol-Myers Squibb's written notice of termination. Molecular Templates plans to reduce costs related to the collaboration agreement.

User Image vuluan98_ Posted - 1 hour ago

$BMY Watch the crowd-sourced stock and options alerts hit the target prices => https://shorturl.at/dgM12

User Image Johnny_Lever Posted - 9 hours ago

$BMY First the breakout to push through trendline resistance, then the back-test and now the move higher.

User Image bigbull001 Posted - 10 hours ago

$BMY who's with me for ride to $58

User Image basedpicks Posted - 11 hours ago

$BMY holy shit im actually back to even

User Image Gfunkymonkey Posted - 15 hours ago

$BMY Ouch!!! Well that sucks.

User Image Chartist0_0 Posted - 16 hours ago

$BMY well that’s disappointing. Sold in the ah on the news.

User Image DonCorleone77 Posted - 17 hours ago

$BMY 2 of 2 - Bristol Myers says KRYSTAL-12 trial met primary endpoint in PFS ...."Today's news is an important reinforcement of the power of a targeted therapy for patients with locally advanced or metastatic KRASG12C-mutated lung cancer. FDA approval of KRAZATI in the U.S. has allowed us to provide a new treatment option for these patients, and topline results of the KRYSTAL-12 confirmatory study will build greater trust in the medical and patient community," said Abderrahim Oukessou, M.D., vice president, global program lead, KRAZATI, Bristol Myers Squibb. "We are encouraged by the results from KRYSTAL-12 and look forward to helping more patients with KRASG12C-mutated lung cancer." The company will complete a full evaluation of the available data and looks forward to sharing the results with the scientific community at an upcoming medical conference as well as discussing the results with health authorities.

User Image DonCorleone77 Posted - 17 hours ago

$BMY 1 of 2 - Bristol Myers says KRYSTAL-12 trial met primary endpoint in PFS Bristol Myers Squibb announced that the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer harboring a KRASG12C mutation, met the primary endpoint of progression-free survival and the key secondary endpoint of overall response rate as assessed by Blinded Independent Central Review at final analysis for these endpoints. The study remains ongoing to assess the additional key secondary endpoint of overall survival. Results of the confirmatory trial showed that KRAZATI demonstrated a statistically significant and clinically meaningful benefit in PFS and ORR compared to standard-of-care chemotherapy as a second-line or later treatment for these patients. KRAZATI had no new safety signals and the safety data was consistent with the known safety profile....

User Image DonCorleone77 Posted - 17 hours ago

$BMY 2 of 2 - Bristol Myers: Phase 3 YELLOWSTONE trial did not meet primary endpoint ....senior vice president and head, Immunology, Cardiovascular and Neuroscience development, Bristol Myers Squibb. "While we are disappointed that the primary endpoint was not reached in this first induction trial, we are committed to driving transformative science on behalf of individuals with immune-mediated diseases and would like to thank the investigators and patients who are participating in the YELLOWSTONE clinical trial program."

User Image DonCorleone77 Posted - 17 hours ago

$BMY 1 of 2 - Bristol Myers: Phase 3 YELLOWSTONE trial did not meet primary endpoint Bristol Myers Squibb announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia (ozanimod) in adult patients with moderate to severe active Crohn's disease. The study did not meet its primary endpoint of clinical remission at Week 12. The safety profile of Zeposia in this study was consistent with that observed in previously reported trials. The company will complete a full evaluation of the YELLOWSTONE trial data and work with investigators to share the results with the scientific community in the future. "To date, no S1P modulator has shown an effect in a Phase 3 trial in Crohn's disease, where a high unmet medical need remains for new therapies that offer more patients relief from symptoms and the potential for remission," said Roland Chen, MD....

User Image Stock_Titan Posted - 17 hours ago

$BMY Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung… https://www.stocktitan.net/news/BMY/bristol-myers-squibb-announces-pivotal-krystal-12-confirmatory-trial-md94xf9ngm3y.html

User Image atraiyou Posted - 17 hours ago

$BMY not good….

User Image Stock_Titan Posted - 17 hours ago

$BMY Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease https://www.stocktitan.net/news/BMY/bristol-myers-squibb-provides-update-on-the-first-phase-3-nycdyy1w5hvr.html

User Image LuckyBoy369 Posted - 19 hours ago

@flipsy 100%, our drugs will be used with Mirati's which is owned by $BMY. What might be the New data they are talking about

User Image JDR1983 Posted - 19 hours ago

$BMY Breaking out. Beautiful chart!!!

User Image flipsy Posted - 19 hours ago

$PPBT I think this is the first time they ever mentioned synergy with mutated KRAS inhibitors $BMY

User Image Quantumup Posted - 21 hours ago

Roth MKM raised the Price Target on $CLRB to $28 was $20/Buy, pointing to Q4 results and updates indicating that $CLRB' pivotal Lopofosine I-131 trial delivered strong efficacy and safety in highly refractory Waldenström's macroglobulinemia (WM) patients, handily beating the required success. Roth adds, lopofosine I-131 is also showing benefit in several disease settings, making $CLRB an attractive acquisition target. $bmy

User Image Mc0731 Posted - 21 hours ago

$BMY they’re she goes

User Image 50bps Posted - 23 hours ago

$BMY still lots of work to do but very constructive

User Image Chartist0_0 Posted - 23 hours ago

$BMY people who talk about charts should post a chart like I did.

User Image Quantumup Posted - 1 day ago

Oppenheimer⬆️ $CLRB $12 was $11/Outperform Mgmt remains confident in a 2H24 NDA filing goal, w/ an approval under fast-track possible mid-yr '25. Expects updated data anticipated in May2validate the +VE interim read. Talks w/ Mgmt accent opp4a broader label, supporting OPY confidence in the mkt. $bmy

User Image UltimateTrader_22 Posted - 1 day ago

OTC: $TREIF CSE: $TRUE Download our Investor Presentation Now: https://treatment.com/wp-content/uploads/2024/03/TREATMENT-INVESTOR-MARCH.pdf "We believe everyone deserves great health" $BMY $JNJ $AI #AI

User Image Rubiks_KubeMD Posted - 1 day ago

$BMY this has a LOT of room to run. Chart setting up beautifully

User Image GPS_OS_21_vs_SOC_5 Posted - 1 day ago

@Sczey True Unless You have More than 1 Potential Buyer - In a Bidding War $ABBV $MRK $BMY $PFE @jonnyloitering @Sharkie2023 @bikechain @Expharmaguy

User Image DubK Posted - 1 day ago

@Knewcomer @dvice2 I was saying this weeks back as speculation that it seems company is choosing this direction after Frank’s fireside in January. So I was more pleased than surprised. I like that they finalized that it will be keytruda for triplet which was either $BMY or $MRK. So now that leaves as $MRK as only potential partner. Dr. Shepard’s last job was doing $MRK trials for 6 years through $1B+ partnership. Coincidence🤷🏽‍♂️ Or did $MRK say that before we fork up $$ we want our man in charge. Then they ask him to come along a join a small cap that no one on Wall Street has heard of? Or is it more likely that he got recruited by Frank who convinced him with no prior affiliation to join a small cap journey this late in career? So now I’m speculating that a partnership of some sort with $MRK still has high possibility of happening after trial design is completed.

User Image Tanestein Posted - 1 day ago

$KO $MCD $BMY $CAR Extremely bullish for next week.

User Image JDR1983 Posted - 1 day ago

$BMY chart looks great. Buy!!!

User Image Quantumup Posted - 1 day ago

Jefferies⬆️ $NUVB Buy/$10 was Hold/$1.4 =$3B valuation or 300% upside/not a stretch if pivotal P2B ROS1 lung cancer data is confirmed this yr/early data looks as good as $NUVL/ $TPTX which are $4-5B valuations. This is an under-followed small cap w/ new story w/ this new Tx. $bmy

User Image Modbrand Posted - 1 day ago

$BMY $49.27 avg patiently waiting for $63+

Analyst Ratings
Wells Fargo Equal-Weight Feb 6, 24
Redburn Atlantic Neutral Feb 6, 24
B of A Securities Neutral Jan 3, 24
B of A Securities Buy Dec 27, 23
Cantor Fitzgerald Neutral Nov 15, 23
Deutsche Bank Hold Nov 9, 23
Daiwa Capital Neutral Nov 2, 23
Goldman Sachs Buy Oct 30, 23
Morgan Stanley Underweight Oct 27, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BOERNER CHRISTOPHER S. Chief Executive Offi.. Chief Executive Officer Dec 05 Buy 49.78 2,000 99,560 82,672 12/07/23
BOERNER CHRISTOPHER S. Chief Executive Offi.. Chief Executive Officer Nov 28 Buy 48.86 3,071 150,049 79,384 11/30/23
Samuels Theodore R. II Director Director Nov 20 Buy 49.81 8,500 423,385 35,500 11/21/23
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Aug 24 Sell 61.25 17,986 1,101,642 27,868 08/28/23
Plenge Robert M EVP, Chief Research.. EVP, Chief Research Officer Aug 03 Sell 61.14 732 44,754 6,584 08/07/23
VESSEY RUPERT EVP & President, Res.. EVP & President, Research May 03 Sell 67.06 50,385 3,378,818 47,751 05/04/23
Caforio Giovanni Board Chair and CEO Board Chair and CEO Feb 06 Sell 74.65 240,000 17,916,000 236,104 02/08/23
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Feb 06 Sell 74.69 11,183 835,258 23,043 02/08/23
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Nov 09 Sell 80.45 16,250 1,307,312 34,226 11/14/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 07 Option 54.85 52,604 2,885,329 102,989 11/09/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 07 Sell 78.88 45,910 3,621,381 57,079 11/09/22
Elkins David V EVP, Chief Financial.. EVP, Chief Financial Officer Sep 13 Sell 71.32 133,951 9,553,385 119,786 09/15/22
Elkins David V EVP, Chief Financial.. EVP, Chief Financial Officer Sep 13 Option 48.49 123,277 5,977,702 223,737 09/15/22
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Sep 14 Sell 70.75 25,000 1,768,750 50,476 09/15/22
Caforio Giovanni Board Chair and CEO Board Chair and CEO Jun 13 Sell 74.04 30,000 2,221,200 551,104 06/14/22
LEUNG SANDRA EVP, General Counsel EVP, General Counsel Jun 06 Sell 74.89 65,000 4,867,850 308,627 06/07/22
Caforio Giovanni Board Chair and CEO Board Chair and CEO Mar 21 Sell 71.52 25,000 1,788,000 581,524 03/23/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Mar 16 Option 53.64 47,305 2,537,440 93,613 03/18/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Mar 16 Sell 69.25 74,559 5,163,211 50,385 03/18/22
Santiago Karen Murphy SVP & Controller SVP & Controller Mar 14 Sell 69.195 6,577 455,096 16,704 03/16/22
BOERNER CHRISTOPHER S. EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 14 Sell 69.197 29,532 2,043,526 41,966 03/16/22
Caforio Giovanni Board Chair and CEO Board Chair and CEO Feb 24 Sell 67 30,000 2,010,000 453,455 02/28/22
von Autenried Paul EVP, Chief Informati.. EVP, Chief Information Officer Nov 22 Sell 57.19 51,134 2,924,353 63,536 11/24/21
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 23 Option 48.03 52,213 2,507,790 98,355 11/23/20
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 23 Sell 61.28 57,591 3,529,176 51,343 11/23/20